Market Research Logo

Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2018-2027)

Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2018-2027)

Non-alcoholic Steatohepatitis or NASH is a common term for “silent” liver disease and can result into cirrhosis, in which liver is permanently damaged and after a certain point could lead to death. Currently, no specific medicines for NASH exist, but certain specialty drugs are expected to enter the market in the year 2020.

The global NASH drugs market is expected to witness a lucrative growth due the mounting occurrence of NASH, rising healthcare expenditure, increasing obese patient population, unmet medical needs and sedentary lifestyle. The market is trending with rising pharmaceutical R&D expenditures, development of NASH diagnosis methods and biomarkers, progressing drugs under pipeline and intensifying e-commerce pharmaceutical products sales. However, there are some growth hindering factors in the market including lethargic drug approval process, high treatment cost and associated business risks.

Regionally, the U.S. is expected to hold the leading position in the market, due to constantly increasing prevalence of various types of liver disease and the local companies engaged in the manufacturing of NASH drugs.

The report “Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2018-2027)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. Key players i.e. Gilead Sciences, Inc., Allergan Plc (Tobira), Intercept Pharmaceuticals, Inc., and Genfit SA are being profiled along with their respective financials and growth strategies.


1. Market Overview
1.1 Introduction
Table 1: NAFLD Spectrum and Estimated Advancement Risk
1.2 Causes & Symptoms
1.3 Diagnosis
1.4 Treatment
Table 2: NASH Off-Label Therapies (2017)
Table 3: Potential Phase III NASH Drugs
2. Global NASH Market
2.1 Global NASH Drugs Market Value Forecast
Table 4: Global NASH Drugs Market Value Forecast (2017-2027)
2.2 Global NASH Drugs Market Value Forecast by Drug Class
Table 5: Global NASH Drugs Market Value Forecast by Drug Class (2017/2022/2027)
2.3 Global NASH Off-Label Drugs Market Value Forecast
Table 6: Global NASH Off-Label Drugs Market Value Forecast (2017-2027)
3. Global NASH Therapeutics Market
3.1 Global NASH Therapeutics Market Value Forecast
Table 7: Global NASH Therapeutics Market Value Forecast (2020-2027)
3.2 Global NASH Therapeutics Market Value Forecast by Drug Type
Table 8: Global NASH Therapeutics Market Value Forecast by Drug Type (2022)
Table 9: Global NASH Therapeutics Market Value Forecast by Drug Type (2027)
3.2.1 Global Obeticholic Acid (OCA) Drug Value Forecast
Table 10: Global Obeticholic Acid (OCA) Drug Value Forecast (2020-2027)
3.2.2 Global Obeticholic Acid (OCA) Drug Value Forecast by Region
Table 11: Global Obeticholic Acid (OCA) Drug Value Forecast by Region (2027)
3.2.3 Global Cenicriviroc (CVC) Drug Value Forecast
Table 12: Global Cenicriviroc (CVC) Drug Value Forecast (2020-2027)
3.2.4 Global Cenicriviroc (CVC) Drug Value Forecast by Region
Table 13: Global Cenicriviroc (CVC) Drug Value Forecast by Region (2027)
3.2.5 Global Elafibranor Drug Value Forecast
Table 14: Global Elafibranor Drug Value Forecast (2020-2027)
3.2.6 Global Aramchol Drug Value Forecast
Table 15: Global Aramchol Drug Value Forecast (2022-2027)
3.2.7 Global MGL-3196 Drug Value Forecast
Table 16: Global MGL-3196 Drug Value Forecast (2023-2027)
3.2.8 Global INN-217 Drug Value Forecast
Table 17: Global INN-217 Drug Value Forecast (2023-2027)
3.2.9 Global VK2809 Drug Value Forecast
Table 18: Global VK2809 Drug Value Forecast (2023-2027)
3.3 Global NASH Therapeutics Market Value Forecast by Region
Table 19: Global NASH Therapeutics Market Value Forecast by Region (2022)
Table 20: Global NASH Therapeutics Market Value Forecast by Region (2027)
4. Regional NASH Market
4.1 The U.S. NASH Therapeutics Market Value Forecast
Table 21: The U.S. NASH Therapeutics Market Value Forecast (2022-2027)
4.2 Europe NASH Therapeutics Market Value Forecast
Table 22: Europe NASH Therapeutics Market Value Forecast (2022-2027)
4.3 RoW NASH Therapeutics Market Value Forecast
Table 23: RoW NASH Therapeutics Market Value Forecast (2022-2027)
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Mounting Occurrence of NASH
Table 24: The U.S. NASH Patient Population (2017-2027)
5.1.2 Rising HealthCare Expenditure
Table 25: Global HealthCare Expenditure Per Capita (2013-2017)
5.1.3 Swelling Obese Patient Population
Table 26: Global Obese Patient Population (2013-2017)
5.1.4 Accelerating Economic Growth
Table 27: Global GDP Per Capita (2013-2017)
5.1.5 Unmet Medical Needs
5.1.6 Sedentary Lifestyle
5.2 Key Trends & Development
5.2.1 Rising Pharmaceutical R&D Expenditures
Table 28: Global Pharmaceutical R&D Expenditures (2013-2017)
5.2.2 Development of NASH Diagnosis Methods and Biomarkers
Table 29: Selected NASH Diagnosis Methods and Biomarkers under Development (2018)
5.2.3 Progressing Drugs under Pipeline
Table 30: Drugs under Development for NASH (2018)
5.2.4 Intensifying E-Commerce Pharmaceutical Products Sales
Table 31: Global E-Commerce Pharmaceutical Products Sales (2017-2022)
5.3 Challenges
5.3.1 Lethargic Drug Approval Process
Table 32: Drugs Approval Process
5.3.2 High Treatment Cost
Table 33: NASH Annual Treatment Cost Comparison (2018)
5.3.3 Associated Business Risk
6. Competitive Landscape
6.1 Global NASH Drugs Market
6.1.1 Key Players - Revenue Comparison
Table 34: Key Players - Revenue Comparison (2017)
6.1.2 Key Players – Market Cap Comparison
Table 35: Key Players - Market Cap Comparison (2018)
6.1.3 Key Players – Product Portfolio Comparison
Table 36: Key Players – Product Portfolio Comparison (2018)
7. Company Profiles
7.1 Gilead Sciences, Inc.
7.1.1 Business Overview
Table 37: Gilead Sciences Revenues by Business Segments (2017)
7.1.2 Financial Overview
Table 38: Gilead Sciences Revenues and Net Income (2013-2017)
7.1.3 Business Strategies
Table 39: Gilead Sciences R&D Expenditure (2015-2017)
7.2 Allergan Plc (Tobira)
7.2.1 Business Overview
Table 40: Allergan (Tobira) Net Revenues by Business Segments (2017)
7.2.2 Financial Overview
Table 41: Allergan (Tobira) Net Revenues and Net Loss (2013-2017)
7.2.3 Business Strategies
Table 42: Allergan (Tobira) R&D Expenditures (2015-2017)
7.3 Intercept Pharmaceuticals, Inc.
7.3.1 Business Overview
Table 43: Intercept Pharmaceuticals Product Pipeline (2018)
7.3.2 Financial Overview
Table 44: Intercept Pharmaceuticals Revenue and Net Loss (2013-2017)
7.3.3 Business Strategies
Table 45: Intercept Pharmaceuticals A&P Expenditures (2015-2017)
Table 46: Intercept Pharmaceuticals R&D Expenditures (2015-2017)
7.4 Genfit SA
7.4.1 Business Overview
Table 47: Genfit Product Pipeline (2018)
7.4.2 Financial Overview
Table 48: Genfit Revenues and Net Loss (2013-2017)
7.4.3 Business Strategies
Table 49: Genfit R&D Expenditures (2015-2017)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report